OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Part of paid clinical trials in Eden Prairie, Minnesota.

Sponsor
AstraZeneca
Study ID
NCT06355934
Status
Recruiting

Conditions

  • ATTR Amyloidosis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • no intervention — OTHER
    not applicable, this is an observational retrospective data analysis study; no interventions in the study

Study Details

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Key Dates

Start date
Aug 21, 2023
Status verified
May 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
52,121 participants (estimated)

Arms

  • Arm: ATTR cardiomyopathy
    Patients with Transthyretin Amyloidosis Cardiomyopathy
  • Arm: ATTR polyneuropathy
    Patients with Transthyretin Amyloidosis Neuropathy
  • Arm: ATTR unknown
    Patients with ATTR unknown genotype
  • Arm: ATTR with mixed phenotype
    Patients with ATTR mixed phenotype
  • Arm: ATTR wild type
    Patients with Transthyretin Amyloidosis wild type
  • Arm: ATTR hereditary
    Patients with Transthyretin Hereditary

Primary Outcome Measure

Health Care Resource Utilization (HCRU) - Outpatient visits [ Time Frame: From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteEden PrairieMinnesota55344-

Find similar trials in Eden Prairie, MN

Related Studies